You Position: Home > Paper

Advance in the effectiveness and safety of new oral anticoagulants in the antithrombotic treatment of atrial fibrillation combined with coronary atherosclerotic heart disease

( views:16, downloads:31 )
Author:
No author available
Journal Title:
China Medicine
Issue:
2
DOI:
10.3760/j.issn.1673-4777.2023.02.029
Key Word:
心房颤动;冠心病(冠状动脉粥样硬化性心脏病);经皮冠状动脉介入;新型口服抗凝药

Abstract´╝Ü 心房颤动合并冠心病(冠状动脉粥样硬化性心脏病)抗栓治疗的选择一直是一个难题.在抗血小板的同时也需要抗凝治疗,选择抗栓治疗方案时,兼顾降低出血风险的同时又能取得最大的临床疗效是心房颤动合并冠心病抗栓治疗方案的关键.华法林作为心房颤动传统的抗凝药物,由于其自身的局限性,推动了新型口服抗凝药(NOAC)的兴起,在抗栓治疗中选择口服抗凝药有了新的选择和认识.然而NOAC在心房颤动合并冠心病患者中的临床疗效及安全性仍有一些争议.本文就NOAC应用于心房颤动合并冠心病患者抗栓治疗中的有效性及安全性作一综述.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn